Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Human Genetics Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Trends Genet. 2018 Jun;34(6):466-476. doi: 10.1016/j.tig.2018.03.002. Epub 2018 Mar 29.
Congenital disorders of glycosylation (CDG) are a rapidly expanding group of metabolic disorders that result from abnormal protein or lipid glycosylation. They are often difficult to clinically diagnose because they broadly affect many organs and functions and lack clinical uniformity. However, recent technological advances in next-generation sequencing have revealed a treasure trove of new genetic disorders, expanded the knowledge of known disorders, and showed a critical role in infectious diseases. More comprehensive genetic tools specifically tailored for mammalian cell-based models have revealed a critical role for glycosylation in pathogen-host interactions, while also identifying new CDG susceptibility genes. We highlight recent advancements that have resulted in a better understanding of human glycosylation disorders, perspectives for potential future therapies, and mysteries for which we continue to seek new insights and solutions.
先天性糖基化障碍(CDG)是一类迅速扩展的代谢性疾病,其源于蛋白质或脂质糖基化的异常。由于它们广泛影响多种器官和功能,且缺乏临床一致性,因此临床诊断较为困难。然而,新一代测序技术的最新进展揭示了大量新的遗传疾病,扩展了已知疾病的知识,并在传染病中发挥了关键作用。专门针对哺乳动物细胞模型的更全面的遗传工具揭示了糖基化在病原体-宿主相互作用中的关键作用,同时也确定了新的 CDG 易感性基因。我们重点介绍了最近的进展,这些进展使人们更好地了解了人类糖基化障碍,为潜在的未来治疗方法提供了新的视角,并为我们继续寻求新的见解和解决方案的未解之谜提供了思路。